Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wave Life SciencesWVE -2.04%60 Equity-to-Asset is 0.81 as of Jun. 2026, which is 145% above its 10-year median of 0.33. GuruFocus rates WVE with a GF Score™ of 60/100 and a GF Value™ of $3.86 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, Wave Life Sciences ranks better than 67.54% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Wave Life Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $453.52 Mil. Wave Life Sciences's Total Assets for the quarter that ended in Jun. 2026 was $558.32 Mil.
Therefore, Wave Life Sciences's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.81.
The historical rank and industry rank for Wave Life Sciences's Equity-to-Asset or its related term are showing as below:
WVE'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.31 Med: 0.33 Max: 0.88
Current: 0.81
During the past 13 years, the highest Equity to Asset Ratio of Wave Life Sciences was 0.88. The lowest was -0.31. And the median was 0.33.
WVE's Equity-to-Asset is ranked better than 67.54% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs WVE: 0.81
Wave Life Sciences (NAS:WVE) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Wave Life Sciences Equity-to-Asset Related Terms
Wave Life Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Wave Life Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WVE vs IMMX, CADL, ARDX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Wave Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Wave Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wave Life Sciences (WVE) has a Equity-to-Asset of 0.81 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Wave Life Sciences and its competitors. This is 145% above median its historical median of 0.33. According to the industry distribution chart, Wave Life Sciences ranks #459 out of 1414 companies in the Biotechnology industry, placing it in the top 32.5%.
Is Wave Life Sciences' Equity-to-Asset too high?
Wave Life Sciences' current Equity-to-Asset of 0.81 is 145% above median its 10-year median of 0.33. The Biotechnology industry median Equity-to-Asset is 0.68. Wave Life Sciences' value of 0.81 is 19.1% above this industry median. Based on the distribution chart, Wave Life Sciences ranks #459 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' Equity-to-Asset compare to IMMX and CADL?
According to the Biotechnology industry distribution chart, Wave Life Sciences ranks #459 out of 1414 companies for Equity-to-Asset. This puts Wave Life Sciences in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Wave Life Sciences' value of 0.81 is 19.1% above this benchmark. While the company's 10-year median is 0.33 vs. the industry median of 0.68, Wave Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wave Life Sciences's current Equity-to-Asset of 0.81 is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Wave Life Sciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wave Life Sciences's current Equity-to-Asset is 0.81, which is 145% above median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.86, compared to a current price of $4.81 — trading 24.6% above its estimated fair value. The current Equity-to-Asset is 0.81, which is 145% above median its 10-year median of 0.33 and 19.1% above the Biotechnology industry median of 0.68. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current Equity-to-Asset is 0.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $4.81 is trading 24.6% above its estimated GF Value™ of $3.86.
GuruFocus considers Wave Life Sciences to be Modestly Overvalued.
Key valuation signals for WVE:
Equity-to-Asset: 0.81 (145% above median its 10-year median of 0.33)
GF Value™: $3.86 vs. price of $4.81 (24.6% above fair value)
Industry Position: 19.1% above the Biotechnology median (#459 of 1414)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score
Get the complete analysis for WVE
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
